The Effects of Active Hexose Correlated Compound (AHCC) on Levels of CD4+ and CD8+ in Patients with Epithelial Ovarian Cancer or Peritoneal Cancer Receiving Platinum Based Chemotherapy

Wineeya Suknikhom, Ruangsak Lertkhachonsuk, Tarinee Manchana, Wineeya Suknikhom, Ruangsak Lertkhachonsuk, Tarinee Manchana

Abstract

Background: Adjuvant chemotherapy is a required treatment for most patients with epithelial ovarian cancer (EOC) or peritoneal cancer. However, it has many adverse events which may affect oncologic outcomes. Active hexose correlated compound (AHCC) has been reported to be an immunoenhancer to decrease adverse events of chemotherapy. Materials and Methods: Patients were randomized and allocated to receive either AHCC three grams/day (500mg/ capsule) or placebo. These drugs were administrated as two capsules orally three times a day throughout six cycles of chemotherapy. The primary outcome was a change of CD4+ and CD8+ T cell lymphocytes in peripheral blood samples from baseline to completion of chemotherapy. Secondary outcomes were rate of bone marrow suppression, adverse events and quality of life (QOL) as assessed by Thai version of the Functional Assessment of Cancer Therapy-General (FACT-G). Results: Study outcomes were analyzed in 28 patients, 14 patients in each group. Changes in CD4+ and CD8+ T cell lymphocytes levels were not significantly different between AHCC and placebo group; 43.5/ul (-237.5, 143.3) versus -69.5 /ul (-223.8, 165) for CD4+ level, p=0.61 and 49.5.0 /ul (-80, 153.3) versus 4.0 /ul (-173, 62.5) for CD8+ level, p=0.19. However, CD8+ levels were significantly higher in the AHCC group at the sixth cycle of chemotherapy; 392.5.0 /ul (310.8, 598) versus 259.5 /ul (170.5, 462.3), p=0.03. There was no difference in bone marrow suppression and QOL between the two groups. Adverse events in terms of nausea and vomiting significantly decreased but muscle pain significantly increased in the AHCC group. Conclusions: Changes in CD4+ and CD8+ T cell lymphocytes from baseline were not significantly increased in AHCC group. However, CD8+T cell lymphocytes levels were significantly higher in the AHCC group at the sixth cycle of chemotherapy.

Keywords: Active hexose correlated compound; chemotherapy; epithelial ovarian cancer; immunoenhancer.

Creative Commons Attribution License

Figures

Figure 1
Figure 1
Adverse Events of Chemotherapy
Figure 2
Figure 2
Adverse Events of Chemotherapy
Figure 3
Figure 3
Total FACT-G Score

References

    1. Acvi FY, Li X, Tsuji M, et al. Carbohydrate and T cells: a sweet twosome. SeminImmunol. 2013;25:146–51.
    1. AHCC Thail. Active hexose correlateted compound. 2013. Accessed at .
    1. Dorigo O, Berek J. Biological, Targeted, and Immune Therapy. In: Berek J, Hacker N, editors. Berekand Hacker’s gynecologiconcology. 6th ed. Philadelphia: Wolters Kluwer; 2015. pp. 39–57.
    1. Ferlay J, Parkin DM, Steliarova-Foucher E. Estimates of cancer incidence and mortality in Europe in 2008. Eur J Cancer. 2010;46:765–81.
    1. Gao Y, Zhang D, Sun B. Active hexose correlated compound enhances tumor surveillance through regulating both innate and adaptive immune responses. Cancer Immunol Immunother. 2006;55:1258–66.
    1. Goodman MT, Shvetsov YB. Rapidly increasing incidence of papillary serous carcinoma oftheperitoneum in the United States: fact or artifact? Int J Cancer. 2009;124:2231–5.
    1. Hirose A, Sato E, Fujii H. The influence of active hexose correlated compound (AHCC) on cisplatin-evoked chemotherapeutic and side effects in tumor-bearing mice. Toxicol Appl Pharmacol. 2007;222:152–8.
    1. Hwang WT, Adams SF, Tahirovic E, et al. Prognostic significance of tumor-infiltrating T cells in ovarian cancer: a meta-analysis. Gynecol Oncol. 2012;124:192–8.
    1. Kidd PM. The use of mushroom glucans and proteoglycans in cancer treatment. Altern Med Rev. 2000;5:4–27.
    1. Lee WW, Lee N, Fujii H, et al. Active hexose correlated compound promotes T helper (Th) 17 and 1 cell responses via inducing IL-1βproduction from monocytes in humans. Cell Immunol. 2012;275:19–23.
    1. McGuire WP, Hoskins WJ, Brady MF, et al. Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer. N Engl J Med. 1996;334:1–6.
    1. Mushiake H, Tsunoda T, Nukatsuka M, et al. Dendritic cells might be one of key factors for eliciting antitumor effect by chemoimmunotherapy in vivo. Cancer Immunol Immunother. 2005;54:120–6.
    1. Nakamoto D, Shigama K, Nishioka H, et al. Active hexose correlated compound (AHCC) alleviates gemcitabine- induced hematological toxicity in non-tumor-bearing mice. Int J Clin Med. 2012;3:361–7.
    1. Ozols RF, Bundy BN, Greer BE, et al. Phase III trial of carboplatin and paclitaxel compared with cisplatinand paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol. 2003;21:3194–200.
    1. Siegel R, Naishadham D, Jemal A. Cancer statistics 2012. CA Cancer J Clin. 2012;62:10–29.
    1. Yin Z, Fujii H, Walshe T. Effects of active hexose correlated compound on frequency of CD4+and CD8+T cells producing interferon-gamma and/or tumor necrosis factor-alpha in healthy adults. Hum Immunol. 2010;71:1187–90.
    1. Zhang L, Conejo-Garcia JR, Katsaros D, et al. Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med. 2003;348:203–13.

Source: PubMed

Szponzorok és közreműködők

Egészségi állapot

Kábítószer-beavatkozások

3
Iratkozz fel